KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $71,231.20 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 5,296 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the completion of the transaction, the insider owned 131,831 shares in the company, valued at $1,773,126.95. This represents a 3.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

KalVista Pharmaceuticals Stock Up 0.6%

KALV stock opened at $14.19 on Friday. The firm has a market cap of $717.25 million, a PE ratio of -3.60 and a beta of -0.04. The business has a 50 day moving average of $12.07 and a 200-day moving average of $12.89. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.04. The company had revenue of $13.69 million for the quarter, compared to analysts’ expectations of $6.03 million. On average, research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KALV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Citizens Jmp decreased their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday, November 11th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th. Finally, JMP Securities lifted their price objective on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a research note on Friday, September 12th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.63.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Earned Wealth Advisors LLC bought a new stake in shares of KalVista Pharmaceuticals in the 1st quarter valued at about $44,000. BNP Paribas Financial Markets grew its position in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares during the last quarter. CWM LLC increased its stake in KalVista Pharmaceuticals by 12,636.1% in the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock worth $53,000 after purchasing an additional 4,549 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in KalVista Pharmaceuticals in the 3rd quarter worth approximately $55,000. Finally, Wolverine Asset Management LLC bought a new stake in KalVista Pharmaceuticals in the third quarter valued at approximately $57,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).